PrognomiQ
PrivateLast Round
Series D
Nov 5, 2024
Total Funding Raised
$135M
Company Overview
PrognomiQ operates in Healthcare & Life Sciences and is based in San Mateo, California. Its latest recorded funding round was a Series D round in November 2024.
PrognomiQ is a biotechnology company that develops multi-omics diagnostic test products for the early detection and treatment of cancer and other complex diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PrognomiQ Comparables
Compare PrognomiQ with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Delfi Diagnostics | 86% | |
| Biodesix Inc | 81% | |
| Harbinger Health | 80% |
For institutional investors. Book with your work email.
PrognomiQ Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 5, 2024 | ||||
| Series C | Mar 15, 2022 | ||||
| Series B | Sep 15, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PrognomiQ Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Maverick Ventures | Series C, Series B |
| Fidelity Management & Research Company | Series C, Series B |
| Catalio Capital Management | Series C, Series D |
| Invus Opportunities | Series C |
| T. Rowe Price | Series C, Series B |
| aMoon | Series C, Series D, Series B |
| Wing Venture Capital | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 23, 2026
Monthly visitors grew 40% MoM, reaching 4.1K.
- Nov 18, 2025
Launched ProVue Lung, a blood test for early lung cancer detection.
For institutional investors. Book with your work email.
PrognomiQ Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PrognomiQ's valuation, stock price, and market status.
Is PrognomiQ a public or private company?
PrognomiQ is a private company.
What is the current stock price of PrognomiQ?
PrognomiQ is a private company, so its shares have no public market price. Caplight tracks PrognomiQ's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PrognomiQ worth (valuation)?
Valuation information for PrognomiQ is not publicly available.
Can I buy PrognomiQ stock?
PrognomiQ shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PrognomiQ's last funding round?
PrognomiQ's most recent funding round was Series D on November 5, 2024.
Who are the main investors in PrognomiQ?
Key investors in PrognomiQ include aMoon.
Will PrognomiQ IPO soon?
No public IPO plans have been announced for PrognomiQ.
How can I track PrognomiQ secondary market activity?
Caplight tracks bids, offers, and trades in PrognomiQ's shares on secondary markets.